Venture capital firms have poured tens of billions of dollars into new drug startups over the past several years, greatly expanding the ranks of biotechnology companies both private and public.
But some argue there’s still room for more. Specifically, there’s room for more young biotechs led and run by the scientists and researchers that founded them. While the idea of the scientific entrepreneur isn’t a foreign one, increasingly the highest-profile and best-funded biotech startups are launched from inside the walls of major venture funders like Flagship Pioneering, Third Rock Ventures and Atlas Venture.
